UPDATED: Johnson & Johnson DePuy Synthes President & CEO Michel Orsinger Arrested At Church
UPDATED: March 17, 2016
Proving that Johnson & Johnson & subsidiaries keep encouraging, rewarding and replicating unethical and illegal behavior while placing blame and not taking accountability unless forced accountable:
At least, Johnson & Johnson DePuy Synthes patient victims get to see a little green this St. Patrick’s Day…finally!
Updated: Below original Story: June 2, 2015 Johnson & Johnson DePuy Synthes FDA Recall for Class II LCS Knee Implants
Well if my LinkedIn page is down again on Monday….Really what kind of corporate attorney hides?
But I do know I’d expect nothing less from a company that’s ethically challenged like Johnson & Johnson .
UPDATED: May 8, 2015
UPDATED: May 7, 2015
May 2, 2015
Michel Orsinger per his LinkedIn page President & CEO of Synthes
then became Johnson & Johnson’s DePuy Synthes
Worldwide Chairman, Global Orthopaedics Group Johnson & Johnson
(note the mired in billion dollar fines of DePuy Synthes is distanced in SEO with the new company name)
Fact based evidence over time is the best indicator of the future. Several weeks ago Johnson & Johnson Ethicon Acclarent former executives were arrested and indicted on 18 counts of fraud and now the company’s making headlines with another arrest. Johnson & Johnson’s DePuy Synthes President & CEO Michel Orsinger, 57, tackled a family member outside of church where Radnor police arrested and charged him with simple assault, disorderly conduct and harassment.
Leadership team: from left: I.V. Hall, WW President, Trauma; Michel Orsinger, WW Chairman, DePuy Synthes Companies; Ken Carpenter, V.P. of U.S. Sales, North Region; Dave Urbahns, V.P. WW Marketing Trauma
This type of behavior speaks to leadership pattern at Johnson & Johnson where unethical and or illegal behavior is not only encouraged, it’s replicated and rewarded. Johnson & Johnson DePuy Synthes experienced some forced accountability from the DOJ last year for the company’s faulty ASR and Pinnacle hips which has cost the company more than $2.5 billion so far.
According to the report, a family member saw Orsinger sending text messages while seated in the church and asked to speak with him outside. She allegedly took the phone from Orsinger’s hands and ran off. When he caught up to her, police say Orsinger pulled her hair, then tackled her after she broke free.
Witnesses told police that Orsinger twisted the victim’s arm while trying to get the phone back and had to be pulled away. He has been released on $30,000 bail. James Boyle Radnor Patch
Even God doesn’t like JNJ
Texting? In church? Wow unless he was giving the approval to pay hundreds of millions to Johnson & Johnson DePuy Synthes hip victims I can’t imagine what would be so important. If Johnson & Johnson is going to continue to encourage, replicate and rewarded unethical and or illegal behavior they may want to think about adding a bail bondsman division.
Thank you to the Killing My Career reader for passing along the story; and, message boards like Medtech[y] and Cafepharma that afford employees the opportunity to expose negative truths the company would rather remain hidden-the worst nightmare to a corrupt company and best friend to frustrated employees.
UPDATED: May 7, 2015
Michel Orsinger has informed me of his intention to pursue other opportunities outside Johnson & Johnson and is stepping down from his role as Worldwide Chairman, Global Orthopaedics, as of today. He will support Gary over the coming months as the newly combined Medical Devices group transitions. “I am proud of the people of DePuy Synthes and the successful orthopaedics business created through the integration and transformation,” Michel said.
From Alex Gorsky, May 6, 2015
UPDATED: April 8,2015
Patterns In Fraud: Unethical companies change names to distance from crimes
As highlighted and predicted above companies often change names in order to distance from unethical and or illegal behavior which is the opposite of what an ethical company does. Building a product that’s identifiable in a market is a goal of any company and when an established company changes names under the #PRSpin of reorganization it’s #PRSpunUnSpun: Johnson & Johnson’s attempt to distance from unethical and or illegal behavior where their own negative truth is hurting their image and in turn possibly profits.
#PRSpin: Michel Orsinger is out as head of Johnson & Johnson’s (J&J) DePuy Synthes orthopedics business following a reorganization of J&J’s medical device businesses.
#PRSpinUnSpun: The company is creating a single Medical Devices Group by integrating its surgery and orthopedics business under the leadership (?) of Gary Pruden, head of the surgery business. Pruden will become worldwide chairman, Johnson & Johnson Medical Devices. Orsinger told the company of his intention to pursue other opportunities outside J&J. The reason Johnson & Johnson has decided to integrate under the new name Medical Devices is that all the unethical and illegal behavior from Johnson & Johnson’s Ethicon’s Gynecare, Johnson & Johnson’s Ethicon’s Acclarent and Johnson & Johnson’s DePuy Synthes falls off in SEO.
The companies crimes no longer follow them which prevents patients and consumers from knowing all the facts to make the best educated decisions which is unethical and the Department of Justice should make it illegal if a company was forced to be accountable through million or billion dollar fines, as Johnson & Johnson clearly has multiple times. No company name change for at least five years (barring any additional fines) which would mean: Johnson & Johnson could not ever change any subsidiary name to distance from crimes.
Orsinger’s job loss is not related to reorganization because that’s inconsistent & contradictory to the 2011 merger and more likely to do with his recent arrest that he decided to move on at this time.
#MEDIA Google’s EU does not apply in the U.S. and unethical companies engaging in illegal activity should not be allowed to distance from their crimes with a simple name change-they do not have the right to be forgotten. Please be sure and add to the new Johnson & Johnson Medical Devices all former companies that apply: ex: formerly DePuy Synthes, Ethicon, Gynecare, Acclarent as a means to help educate the patients, consumers, employees and taxpayers alike.
Does Johnson & Johnson like to play victim when it comes to acquisitions?
Again according to Michel Orsinger’s LinkedIn page he’s been with Synthes since July 2004 and was retained (or his actions were encouraged, replicated and rewarded) during the largest Johnson & Johnson buyout when their DePuy subsidiary purchased Synthes for a record $21.3 billion in 2011. Ironically also Johnson & Johnson’s largest DOJ fines over $2.5 billion were from the subsidiary, DePuy Synthes. For those unfamiliar with this blinding billion dollar fairy tale of fraud:
Four former executives of medical device manufacturer Synthes, Inc., who went to federal prison for their role in an illegal clinical trial of bone cement, are out of prison now but probably won’t be working in health care anytime soon.
Michael Huggins, Thomas Higgins, Richard Bohner and John Walsh were officially excluded from federal health-care programs on Tuesday, meaning no company employing them will be eligible to receive reimbursement for services or drugs through programs such as Medicare and Medicaid. Given the private sector’s dependence on government money, companies rarely hire people on the excluded list. Philly
Phew! Good thing all the fraud fell off when Johnson & Johnson bought the company. It’s tough to tell from Michel Orsinger’s LinkedIn page just exactly what he did (that’s inconsistent & contradictory) for Synthes during the height of the company’s pre-purchase fraud and perhaps that’s by design.
Orsinger is getting $51.9 million for leaving the old company and a multimillion dollar pay package from the new company. His new base salary of $700,000 will be a cut in pay from his old firm, but he will have some lucrative bonus opportunities. If he can make do clipping coupons for three years, he will get a stock package worth $17.2 million.
It certainly wouldn’t look very good if this very public story of Synthes killing people showed that Johnson & Johnson knowingly and willfully decided to retain an executive possibly linked to previous crime. That might be considered encouraging, replicating and rewarding unethical and or illegal behavior on Johnson & Johnson’s part.
So it shouldn’t be too shocking to Johnson & Johnson that they’re in the position (and by that I mean bent over by the DOJ with no lube) they’re in now regarding DePuy Synthes because they’ve been complicit which appears to be a pattern in their own company that they encourage, replicate and reward regarding among other things, acquisitions.
Updated: June 2, 2015 Johnson & Johnson DePuy Synthes FDA Recall for Class II LCS Knee Implants
Please take the anonymous #KnowYourValue survey